Press Releases AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
2.015 ^USD	-1.23%		-0.25%	-90.17%

May. 16	Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating	MT
May. 14	AN2 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights	May. 14	BU
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights	Mar. 28	BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	Mar. 25	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	Mar. 11	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	Mar. 03	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	Feb. 24	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	Feb. 15	PR
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease	Feb. 13	AQ
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease	Feb. 12	BU
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference	Jan. 30	BU
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights	Nov. 09	BU
AN2 Therapeutics to Present at Upcoming Investor Conferences	Nov. 06	BU
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease	23-10-18	BU
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023	23-10-11	BU
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria	23-09-26	BU
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex Lung Disease	23-09-14	AQ
AN2 Therapeutics : Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ~230 patients - Form 8-K	23-09-13	PU
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease	23-09-13	BU
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock	23-08-15	BU
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights	23-08-10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Press Releases

Filters